Furthermore, we observed a significant increase in PAK1 expression in CML patients with FUBP3 deletion compared to those without deletion (p ≤ 0.05) and control samples (p ≤ 0.0001) (Figure 6H). The gene discussed is FUBP3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.